Actuate Therapeutics, Inc.ACTU
Price (close)
$0.68
Market cap
$16.3M
P/E
—
Revenue (TTM)
—
Net income
-$20.5M
Dividend yield
—
1-year total return
-89.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Actuate Therapeutics, Inc. does.
company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen
synthase kinase-3 (“GSK-3”). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer
biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$24.7M | -$27.3M | -$22.2M |
More on ACTU.
- Actuate Therapeutics, Inc. summary
- Actuate Therapeutics, Inc. financial statements
- Actuate Therapeutics, Inc. key metrics
- Actuate Therapeutics, Inc. health scores and style box
- Actuate Therapeutics, Inc. earnings
- Actuate Therapeutics, Inc. dividends
- Actuate Therapeutics, Inc. valuation
- Actuate Therapeutics, Inc. ownership and insiders
- Actuate Therapeutics, Inc. peers
Figures from Actuate Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.